A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Latest Information Update: 15 Nov 2024
Price :
$35 *
At a glance
- Drugs Trastuzumab (Primary) ; Tucatinib (Primary) ; Fulvestrant
- Indications Advanced breast cancer; Biliary cancer; Brain cancer; Cervical cancer; Non-small cell lung cancer; Solid tumours; Urogenital cancer; Uterine cancer
- Focus Therapeutic Use
- Sponsors Seagen
- 25 Oct 2024 Results(As of Nov 1, 2023, n=217) assessing efficacy, safety and biomarker analysis presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics
- 04 Jun 2024 Results ( As of Nov 1, 2023, n=31) assessing efficacy and safety results of TUC combined with Tras in pts with previously treated HER2-mut MBC presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 29 Apr 2024 According to Pfizer media release, data from this trial will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting